This paper examines the relationship between Imperial Chemical Industries (ICI), the company that discovered tamoxifen, and Dr Craig Jordan, who played a major part in its success as a breast cancer drug, and who worked as a consultant for the company, but without ever being paid a consultancy fee. Instead, ICI funded junior staff working in his laboratory on topics of his choice. They later paid his expenses as an expert witness in patent-litigation cases, as a result of which the US became a major lucrative market for tamoxifen, and ICI’s other anti-cancer drugs. This case study illustrates that, like consultants, drugs play an important part at the boundary between the academic and industrial spheres. However, even if it is blurred, the boundary remains. Owing to the secrecy that often surrounds industrial research, this boundary may lead to a different understanding of what constitutes innovation, and to different narratives with regard to respective contributions.

中文翻译：

---

Imperial Chemical Industries 和 Craig Jordan，“第一位他莫昔芬顾问”，1960 年代至 1990 年代

本文考察了发现他莫昔芬的帝国化学工业公司 (ICI) 与 Craig Jordan 博士之间的关系，后者在其作为乳腺癌药物的成功中发挥了重要作用，并担任该公司的顾问，但没有一直被支付咨询费。取而代之的是，ICI 资助了在他实验室工作的初级员工，研究他选择的主题。他们后来在专利诉讼案件中支付了他作为专家证人的费用，因此美国成为他莫昔芬和 ICI 其他抗癌药物的主要利润丰厚的市场。本案例研究表明，与顾问一样，药物在学术界和工业界之间的边界上发挥着重要作用。然而，即使它变得模糊，边界仍然存在。由于工业研究经常处于保密状态，